期刊
BIOMARKERS IN MEDICINE
卷 12, 期 9, 页码 1035-1048出版社
FUTURE MEDICINE LTD
DOI: 10.2217/bmm-2018-0157
关键词
anti-TK1 antibodies; biomarker; breast cancer; cell culture; complementary biomarker; Hodgkin; leukemia; lymphoma; proliferation; prostate cancer; solid tumors; TK1; TK 210 ELISA; translational biomarker
Thymidine kinase 1 (TK1) is a key enzyme in DNA precursor synthesis. It is upregulated during the S phase of the cell cycle and its presence in cells is an indicator of active cell proliferation. In studies since the 1980s, TK1 has been shown as a clinically valuable biomarker for the management of hematological malignancies. However, TK1 activity assays may underestimate serum TK1 in subjects with solid tumors limiting its sensitivity. The development of TK1 immunoassays has made the assay of TK1 more widely available and increased its applicability to solid tumor diseases. This paper will review TK1 as a tumor biomarker with emphasis on recent studies and technologies plus highlight its potential in drug discovery and as a therapeutic target.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据